Weighing the Evidence for PCI Decision-Making in Patients with Stable CAD
Since the first percutaneous coronary intervention (PCI) was performed 35 years ago, there have been profound and sustained evolutions in catheter-based revascularization that has shifted the treatment of patients with coronary artery disease (CAD) largely away from an initial pharmacologic approach to one that has increasingly emphasized an anatomically-driven management strategy. Because there are abundant clinical trials data that support the benefit of urgent/emergent PCI in patients with ST-segment elevation myocardial infarction or non-ST-segment elevation acute coronary syndromes (ACS) in reducing death or myocardial infarction (MI),1-6 there has been an expanding use of PCI and physician embracement of coronary stenting that has revolutionized patient management and clinical outcomes in these high-risk patients. (SELECT FULL TEXT TO CONTINUE)
- comparative effectiveness
- coronary heart disease
- ischemic heart disease
- percutaneous coronary intervention
- Received March 14, 2012.
- Accepted March 16, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited